Threshold Pharmaceuticals, Inc.  

(Public, NASDAQ:THLD)   Watch this stock  
Find more results for Robert L. Tillman
-0.01 (-0.26%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.80 - 3.92
52 week 2.58 - 5.41
Open 3.86
Vol / Avg. 355,274.00/817,554.00
Mkt cap 280.40M
P/E     -
Div/yield     -
EPS -0.40
Shares 71.33M
Beta 2.96
Inst. own 61%
Jul 30, 2015
Q2 2015 Threshold Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 19, 2015
Threshold Pharmaceuticals Inc at UBS Global Healthcare Conference
Apr 30, 2015
Q1 2015 Threshold Pharmaceuticals Inc Earnings Release
Mar 3, 2015
Q4 2014 Threshold Pharmaceuticals Inc Earnings Release
Mar 2, 2015
Threshold Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -303.02% -146.61%
Operating margin -261.21% -212.27%
EBITD margin - -203.38%
Return on average assets -57.21% -25.02%
Return on average equity - -
Employees 62 -
CDP Score - -


Suite 300, 170 Harbor Way
United States - Map
+1-650-4748200 (Phone)
+1-650-4742529 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Threshold Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing therapeutic agents that selectively target tumor cells for the treatment of cancer patients. The Company’s lead investigational small molecule, TH-302, is being evaluated in two pivotal Phase III clinical trials and multiple earlier-stage clinical trials. The Company has a global license and co-development agreement for TH-302 with Merck KGaA, with an option to co-commercialize in the United States. As a prodrug, TH-302 is designed to remain essentially inactive in normal tissues, but to activate under conditions of tumor hypoxia. Upon activation, TH-302 releases bromo isophosphoramide mustard (Br-IPM), a potent cytotoxin that kills cells by causing DNA to crosslink. In March 2013, Threshold announced the acquisition of [18F]-HX4 from Siemens Healthcare, to develop [18F]-HX4 to determine a patient’s tumor hypoxia profile.

Officers and directors

Harold E. Selick Ph.D. Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Stewart M. Kroll Senior Vice President, Clinical Development
Age: 56
Bio & Compensation  - Reuters
Robert L. Simon Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 70
Bio & Compensation  - Reuters
Joel A. Fernandes Vice President - Finance, Controller
Age: 45
Bio & Compensation  - Reuters
Nipun Davar Ph.D. Vice President - Pharmaceutical Development and Manufacturing
Age: 47
Bio & Compensation  - Reuters
Tillman Pearce M.D. Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Jeffrey W. Bird M.D., Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Bruce C. Cozadd Independent Director
Age: 51
Bio & Compensation  - Reuters
David R. Hoffmann Independent Director
Age: 70
Bio & Compensation  - Reuters
Wilfred E. Jaeger M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters